A case of an ALS patient with an SQSTM1 mutation — implications for the p62/NF-κB/Nrf2/autophagy pathways in the selection of individualised therapeutic strategies: a preliminary report
Folia Medica Cracoviensia · 2025
DOI: 10.24425/fmc.2025.156692 ↗Kurz gefasst
Fallbericht in der Zeitschrift Folia Medica Cracoviensia, 2025. Verfasst von Kamila Żur-Wyrozumska. Beteiligte Einrichtung: Center for Innovative Medical Education, Jagiellonian University Medical College, Kraków, Poland. kamila.zur-wyrozumska@uj.edu.pl. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Sequestosome-1 Protein.
Abstract (Originalsprache)
Introduction
Amyotrophic lateral sclerosis (ALS) represents a heterogeneous group of neurodegenerative disorders sharing a common ALS phenotype but arising from diverse genetic and molecular mechanisms. Among the genes implicated in ALS, SQSTM1, encoding the multifunctional protein p62, plays a pivotal role in maintaining neuronal homeostasis through the regulation of autophagy and the crosstalk between NF-κB and Nrf2 pathways. Disruption of these mechanisms contributes to oxidative stress, neuroinflammation, and protein aggregation in motor neurons. Material and Methods: A comprehensive genetic analysis, including next-generation sequencing (NGS), whole-exome sequencing (WES), and multiplex ligation-dependent probe amplification (MLPA), was performed in a patient clinically diagnosed with ALS. Literature data regarding the role of SQSTM1, NF-κB/ Nrf2 signaling, and autophagy modulation in ALS pathogenesis were reviewed to contextualize the findings. Case Presentation: We describe a 49-year-old woman with a 12-month history of progressive bulbar- onset ALS. Genetic testing revealed a heterozygous SQSTM1 c.1175C>T (p.Pro392Leu) variant inherited from her father, classified as likely pathogenic. The patient received dimethyl fumarate (Nrf2 activator), celecoxib ( NF-κB inhibitor), and rapamycin (mTOR pathway modulator) as part of an individualized treatment strategy.
Discussion
Mutations in SQSTM1 contribute to ALS pathogenesis through dysregulation of autophagy, impaired protein clearance, and excessive neuroinflammation mediated by NF-κB activation. The interplay between NF-κB and Nrf2 signaling pathways suggests that targeted therapeutic modulation may attenuate neurodegeneration. The patient’s case illustrates the clinical and molecular heterogeneity of ALS and supports the concept of pathway-specific, precision medicine approaches.
Conclusions
This case highlights the relevance of SQSTM1-related pathogenic mechanisms within the heterogeneous ALS spectrum and underscores the importance of advanced genetic testing for identifying candidates for personalized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Innovative Medical Education, Jagiellonian University Medical College, Kraków, Poland. kamila.zur-wyrozumska@uj.edu.pl.
Zitieren
APA
Żur-Wyrozumska, K. (2025). A case of an ALS patient with an SQSTM1 mutation — implications for the p62/NF-κB/Nrf2/autophagy pathways in the selection of individualised therapeutic strategies: a preliminary report. Folia Medica Cracoviensia. https://doi.org/10.24425/fmc.2025.156692
Vancouver
Żur-Wyrozumska K. A case of an ALS patient with an SQSTM1 mutation — implications for the p62/NF-κB/Nrf2/autophagy pathways in the selection of individualised therapeutic strategies: a preliminary report. Folia Medica Cracoviensia. 2025. doi:10.24425/fmc.2025.156692
BibTeX
@article{urWyrozumska2025,
author = {Żur-Wyrozumska, Kamila},
title = {A case of an ALS patient with an SQSTM1 mutation — implications for the p62/NF-κB/Nrf2/autophagy pathways in the selection of individualised therapeutic strategies: a preliminary report},
journal = {Folia Medica Cracoviensia},
year = {2025},
doi = {10.24425/fmc.2025.156692}
}
EUVIMED